About
Genuine Biotech Limited is facing a significant decline in revenue and tight cash flow due to the waning market demand for its core product Azvudine and the termination of its cooperation with FOSUN PHARMA, under pressure from a listing bet agreement. The company applied for a listing on the Hong Kong Stock Exchange for the third time in November 2025, after two previous applications were unsuccessful. Azvudine needs to complete confirmatory clinical research before 2026
WuXi AppTec has been awarded Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO industry for the ninth consecutive year. This recognition highlights WuXi AppTec's integrated CRDMO model, which enhances drug development and delivery. The award underscores the company's commitment to innovation and operational excellence, supporting global pharmaceutical advancements.
BeOne Medicines AG :BEONE MEDICINES LTD - FACILITIES AGREEMENT PROVIDES U.S. DOLLAR-DENOMINATED, B1 REVOLVING LOAN FACILITY OF $140 MILLIONBEONE MEDICINES LTD - FACILITIES AGREEMENT PROVIDES U.S. DOLLAR-DENOMINATED, B2 TERM LOAN FACILITY OF $560 MILLIONBEONE MEDICINES LTD - FACILITIES AGREEMENT PROVIDES RENMINBI-DENOMINATED, A TERM LOAN FACILITY OF ABOUT $300 MILLIONBEONE MEDICINES LTD - ACCORDION FEATURE ALLOWS B LOAN FACILITIES INCREASE TO $700 MILLION - SEC FILING
